^
Association details:
| Biomarker: | EGFR C797S |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | pelcitoclax (APG-1252) (Bcl2 inhibitor, Bcl-xL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 6223: Combination of BCL-2/BCL-xL dual inhibitor APG-1252 and chemotherapeutics overcomes resistance to osimertinib in EGFR mutant NSCLC in preclinical models
Published date:
05/15/2020
Excerpt:
NCI-H1975-C797S derived-xenografts were treated with APG-1252, cisplatin/docetaxel or their combinations….Combination therapy with APG-1252 and cisplatin or docetaxel exhibited synergistic antitumor activity. APG-1252 plus docetaxel combination achieved 100% tumor partial regression (PR). Similar results were demonstrated in a patient-derived xenograft (PDX) tumor model derived from an osimertinib-resistant NSCLC patient harboring 19del-T790M-C797S mutations.
Secondary therapy:
cisplatin; docetaxel
DOI:
10.1158/1538-7445.AM2020-6223
